Vildagliptin + Metformin Hydrochloride

Introduction

Vildagliptin and metformin hydrochloride are combined in a single medication to manage type 2 diabetes mellitus. Vildagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor, and metformin hydrochloride is a biguanide class drug. The combination helps control blood sugar levels in patients who are unable to achieve adequate glycemic control with metformin alone.

Uses

The combination of vildagliptin and metformin hydrochloride is used to:

• Improve glycemic control in adults with type 2 diabetes mellitus.
• Complement lifestyle changes such as diet and exercise to manage blood glucose levels.
• Provide an option for patients who have not achieved sufficient glycemic control with metformin alone.

Mechanism of Action

Vildagliptin works by inhibiting the enzyme DPP-4, which in turn increases the levels of incretin hormones. These hormones enhance insulin secretion and decrease glucagon levels in response to meals. Metformin hydrochloride decreases hepatic glucose production and enhances insulin sensitivity in muscle and fat tissues, leading to improved glucose uptake and reduced blood glucose levels.

How Long Does It Take to Work?

The combination therapy typically starts to show effects on blood glucose levels within a few weeks of initiation. Optimal glycemic control may take several weeks to months of continuous therapy.

Absorption

Vildagliptin is absorbed quickly and reaches peak plasma concentrations within 1-2 hours after oral administration. Metformin hydrochloride is absorbed more slowly, with peak plasma concentrations occurring within 2-3 hours.

Route of Elimination

Vildagliptin is primarily eliminated through the kidneys, with approximately 70% of the dose excreted in the urine. Metformin hydrochloride is also primarily excreted via the kidneys, with about 90% of the dose being eliminated unchanged in the urine.

Dosage

Typical dosages are:

• Vildagliptin: 50 mg twice daily
• Metformin hydrochloride: 500 mg to 1000 mg twice daily

Administration

This medication is usually administered orally in tablet form. It is recommended to take it with meals to minimize gastrointestinal side effects. The dose should be adjusted based on blood glucose monitoring and healthcare provider recommendations.

Side Effects

Common side effects include:

• Gastrointestinal issues (e.g., nausea, diarrhea, abdominal pain)
• Headache
• Fatigue

• Pancreatitis (with vildagliptin)
• Lactic acidosis (a rare but serious condition associated with metformin)

Toxicity

Toxicity concerns for vildagliptin are rare but may include severe abdominal pain or signs of pancreatitis. For metformin, acute toxicity can lead to lactic acidosis, characterized by symptoms such as rapid breathing, confusion, and severe weakness. Immediate medical attention is required in cases of suspected toxicity.

Precautions

Precautions should be taken in individuals with:

• Kidney impairment
• History of pancreatitis
• Liver disease
• Heart failure

Interaction

Drug interactions include:

• Vildagliptin may interact with other medications that affect renal function or blood glucose levels.
• Metformin may interact with contrast agents used in imaging procedures, potentially increasing the risk of lactic acidosis.

Disease Interaction

Use with caution in patients with:

• Kidney or liver disease
• Heart disease
• Conditions increasing the risk of lactic acidosis

Drug Interaction

Interactions may occur with:

• Diuretics or other antihypertensive agents
• Other glucose-lowering medications
• Certain antibiotics and antifungal agents

Food Interactions

Food does not significantly affect the absorption of vildagliptin. However, taking metformin with food can help reduce gastrointestinal side effects. Avoiding excessive alcohol intake is recommended as it can increase the risk of lactic acidosis.

Pregnancy Use

The safety of vildagliptin and metformin during pregnancy has not been fully established. It is generally recommended to use insulin or other medications with a better-known safety profile during pregnancy. Consult a healthcare provider for appropriate alternatives and management.

Lactation Use

Both vildagliptin and metformin are excreted in breast milk in small amounts. The use of this combination during lactation should be carefully considered, weighing the benefits against potential risks. Consult a healthcare provider for guidance.

Acute Overdose

Acute overdose of vildagliptin may lead to symptoms such as nausea or hypoglycemia. Overdose of metformin may cause lactic acidosis. Immediate medical attention is required for suspected overdose, with treatment focusing on supportive care and addressing any complications.

Contraindication

Contraindications include:

• Severe renal impairment or dialysis
• Hypersensitivity to either vildagliptin or metformin
• Severe metabolic acidosis

Use Direction

Follow the prescribed dosage and administration instructions provided by your healthcare provider. Regular monitoring of blood glucose levels and kidney function is necessary. Adjustments to the dose should be made based on medical advice.

Storage Conditions

Store the medication at room temperature, between 15°C and 30°C (59°F and 86°F). Keep in a dry place away from direct sunlight and moisture. Ensure the product is kept out of reach of children and used within its expiration date.

Volume of Distribution

The volume of distribution for each component is:

• Vildagliptin: Approximately 71 liters
• Metformin: Approximately 654 liters

Half Life

Half-lives are:

• Vildagliptin: Approximately 2.1 hours
• Metformin: Approximately 1.5 to 3 hours

Clearance

Clearance rates are:

• Vildagliptin: Primarily renal clearance with approximately 70% excreted in the urine
• Metformin: Excreted mainly through the kidneys with about 90% of the dose eliminated unchanged